Clinical Trial

A Study to Learn More About Tukysa Once it is Out in the Korean Market

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The objectives of the re-examination system in Korea is to re-confirm the clinical usefulness of the product through collecting, reviewing, identifying and verifying the safety and efficacy information about the product in general practice in Korea. This surveillance is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Laws, the Regulations on Safety of Pharmaceuticals, etc. and the Re-examination Regulation for New Drugs and Others.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-06; most recent amendment 2025-11-14.
Trial Details
NCT Number NCT06873191
Lead Sponsor Pfizer
Conditions HER2-positive Locally Advanced Unresectable, Metastatic Breast Cancer
Enrollment 600 participants
Start Date 2027-01-01
Primary Completion 2029-05-01 (estimated)
Study Completion 2029-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-17